Novartis AG has acquired U.S.-based Selexys Pharmaceuticals Corp., a developer of therapeutics for blood and inflammatory disorders, the Swiss drug maker said in a statement Monday. The terms of the deal could amount to up to $665 million in upfront, acquisition and milestone payments, Novartis said. The move came after the receipt of results from a trial evaluating Selexys’s SelG1, a treatment for pain related to sickle-cell disease. Novartis exercised a right to acquire Oklahoma City-based Selexys that it obtained in 2012. Shares in Novartis fell 1.5% in early trading Monday.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News